Retinal Neurodegeneration as an Early Manifestation of Diabetic Eye Disease and Potential Neuroprotective Therapies.

Publications // Roomasa Channa // Feb 26 2019

PubMed ID: 30806815

Author(s): Zafar S, Sachdeva M, Frankfort BJ, Channa R. Retinal neurodegeneration as an early manifestation of diabetic eye disease and potential neuroprotective therapies. Curr Diab Rep. 2019 Feb 26;19(4):17. doi: 10.1007/s11892-019-1134-5. Review. PMID 30806815

Journal: Current Diabetes Reports, Volume 19, Issue 4, Feb 2019

PURPOSE OF REVIEW Diabetic retinopathy (DR) is a major cause of visual impairment and blindness throughout the world. Microvascular changes have long been regarded central to disease pathogenesis. In recent years, however, retinal neurodegeneration is increasingly being hypothesized to occur prior to the vascular changes classically associated with DR and contribute to disease pathogenesis.

RECENT FINDINGS There is growing structural and functional evidence from human and animal studies that suggests retinal neurodegeneration to be an early component of DR. Identification of new therapeutic targets is an ongoing area of research with several different molecules undergoing testing in animal models for their neuroprotective properties and for possible use in humans. Retinal neurodegeneration may play a central role in DR pathogenesis. As new therapies are developed, it will be important to develop criteria for clinically defining retinal neurodegeneration. A standardization of the methods for monitoring neurodegeneration along with more sensitive means of detecting preclinical damage is also needed.